Aeglea Biotherapeutics, Inc. News Releases http://ir.aegleabio.com/ Aeglea Biotherapeutics, Inc. News Releases en Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-doses-first-patient-pivotal-phase-3-peace Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas , June 03, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation Mon, 03 Jun 2019 08:30:00 -0400 Aeglea Biotherapeutics, Inc. News Releases 8456 Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-participate-upcoming-investor-and AUSTIN, Texas , May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn , M.B. Thu, 30 May 2019 08:30:00 -0400 Aeglea Biotherapeutics, Inc. News Releases 8446 Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-reports-first-quarter-2019-financial Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from February 2019 Public Offering Extends Cash Runway Through Q1 of 2021 Pivotal Phase 3 Trial of Tue, 07 May 2019 07:45:00 -0400 Aeglea Biotherapeutics, Inc. News Releases 8381 Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-announces-new-positive-phase-12-data Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilarginase Clinically Impactful Responses Captured by Mobility and Adaptive Behavior Assessments Management to Host Conference Call at 8:30 a.m. ET on Monday, April 8 AUSTIN, Texas , April 07, 2019 (GLOBE NEWSWIRE) -- Sun, 07 Apr 2019 19:15:00 -0400 Aeglea Biotherapeutics, Inc. News Releases 8341 Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-present-updated-phase-12-data Management to Host Conference Call at 8:30 a.m. ET on Monday, April 8 AUSTIN, Texas , April 01, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic Mon, 01 Apr 2019 08:00:00 -0400 Aeglea Biotherapeutics, Inc. News Releases 8331 Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-participate-upcoming-investor-conferences AUSTIN, Texas , March 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that Anthony G. Quinn , M.B. Thu, 28 Mar 2019 08:30:00 -0400 Aeglea Biotherapeutics, Inc. News Releases 8326 Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-reports-fourth-quarter-and-full-year-2018 On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with Pegzilarginase Cancer Indication-Phase 2 Combination Study Initiated Gross Proceeds of $69 Million from February 2019 Public Thu, 07 Mar 2019 16:05:00 -0500 Aeglea Biotherapeutics, Inc. News Releases 8266 Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-host-fourth-quarter-and-full-year-2018 AUSTIN, Texas , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced plans to host its fourth quarter Thu, 28 Feb 2019 08:00:00 -0500 Aeglea Biotherapeutics, Inc. News Releases 8241 Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-announces-pricing-600-million-public AUSTIN, Texas , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (Nasdaq:AGLE) a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced the pricing of an underwritten Wed, 06 Feb 2019 00:15:00 -0500 Aeglea Biotherapeutics, Inc. News Releases 8171 Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock http://ir.aegleabio.com/news-releases/news-release-details/aeglea-biotherapeutics-announces-proposed-public-offering-1 AUSTIN, Texas , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it intends to offer and sell, Tue, 05 Feb 2019 17:15:00 -0500 Aeglea Biotherapeutics, Inc. News Releases 8166